Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients.
about
The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implicationsChanges in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDSHigh frequency of Fredrickson's phenotypes IV and IIb in Brazilians infected by human immunodeficiency virusAchieving American Diabetes Association goals in HIV-seropositive patients with diabetes mellitusProtease inhibitor related type III hyperlipoproteinaemia is common and not associated with apolipoprotein-E E2/E2 phenotypeMetabolic effects of indinavir in healthy HIV-seronegative menBrain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individualsAntiretroviral therapy exposure and insulin resistance in the Women's Interagency HIV study.Hyperglycemia associated with protease inhibitors in an urban HIV-infected minority patient population.Disorders of glucose metabolism in patients infected with human immunodeficiency virus.Interactive effects of HIV/AIDS, body mass, and substance abuse on the frontal brain: a P300 studyGlucose disorders associated with HIV and its drug therapy.The New Epidemiology of HIV-Related Kidney Disease.Risk of diabetes mellitus in persons with and without HIV: a Danish nationwide population-based cohort study.Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus.Insulin resistance and adipokines serum levels in a caucasian cohort of hiv-positive patients undergoing antiretroviral therapy: a cross sectional study.Nutrition and HIV infection.Protease inhibitors and decreased birth weight in HIV-infected pregnant women with impaired glucose tolerance.Evaluation and management of dyslipidemia in patients with HIV infection.HIV protease inhibitors and obesityHIV and HAART-Associated DyslipidemiaThiazolidinediones could improve endothelial dysfunction and risk of premature coronary heart disease in HIV-infected patients.Hyperglycemia enhances kidney cell injury in HIVAN through down-regulation of vitamin D receptorsBoosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers.The metabolic effects of lopinavir/ritonavir in HIV-negative menIndinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study.Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factorsInsulin resistance in HIV protease inhibitor-associated diabetes.Molecular Mechanisms for Altered Glucose Homeostasis in HIV InfectionEpidemiology and management of antiretroviral-associated cardiovascular disease.Relation of body composition to body mass index in HIV-infected patients with metabolic abnormalitiesIncreased intramyocellular lipid accumulation in HIV-infected women with fat redistribution.HIV protease inhibitors, the lipodystrophy syndrome and polycystic ovary syndrome--is there a link?Lack of an effect of protease inhibitor use on glucose tolerance during pregnancyInsulin resistance by homeostasis model assessment in HIV-infected patients on highly active antiretroviral therapy: cross-sectional study.Update on HIV lipodystrophy.Coronary heart disease risk, dyslipidemia, and management in HIV-infected persons.Vitamin D deficiency is associated with silent coronary artery disease in cardiovascularly asymptomatic African Americans with HIV infection.Risk factors for new-onset diabetes mellitus in patients receiving protease inhibitor therapyAbnormal glucose metabolism among older men with or at risk of HIV infection
P2860
Q24598812-4962838B-54E8-4926-B390-0477EC781AF9Q24792952-836C664B-26AA-4B08-96D7-60259E83707BQ24814179-5B0A24EC-37A5-4FBC-B8AD-B305A1474900Q28222271-E09AC053-601C-44DE-A2F9-52F7215BA402Q28344599-F24B071E-8724-416B-A7D4-670DBCEFF6D3Q28366603-BC382B6C-245D-40C8-9531-BA7946843391Q33614467-4F478BBE-9608-4FF3-9620-6FA90B76CF14Q33927532-8CD8E625-A858-4B38-9873-D94D2EA8A37AQ33941936-881CEB23-EDF1-45AC-87CD-2F5040B40928Q34092346-A21F7C6A-07BA-44D1-BBCD-078DFA993DBCQ34164091-AF4DD768-76B9-4BC1-9B65-8131D807000FQ34191314-84005818-FF60-4189-8352-C2034EFB746DQ34307868-E205AF1A-B37F-4AA6-AB32-1ADFC9263E90Q34415980-1DB45009-607F-42D3-AACC-6BF66C4CFE67Q34461377-20214515-D043-4D10-8C9F-0627E323F0BBQ34564051-3E279FBF-D4B1-464B-95AA-0FB2B41F4F90Q34564488-8113D73B-072C-4D58-8CED-2AC9E4FF2B72Q34705263-D5DA6055-74C1-42F4-B4A1-BCF1046C18EEQ34743413-9D2F3C52-D0C6-436B-AE31-B865C833F426Q34792983-593B2B10-3311-4C8C-965E-D1B53F6544ABQ35020217-462E45D3-6269-4B42-B2FC-A93FBA8531CEQ35030013-4F4725DD-773B-46C9-84C1-BBED40A969E1Q35141509-4325CFFD-A8AB-420C-BAA3-C9B7D8C05F42Q35188653-F63C01B6-C9CF-46BC-9E5A-1CE97D37B4EDQ35194394-89F109F0-E147-48E2-8671-60FDC290C64DQ35195035-0154EB99-6B73-4B0C-AAD6-27B5A116BE7CQ35206635-32375C3D-028A-43E2-BB95-70EA749E5474Q35237635-FDCB2073-A4BF-4D04-8F32-C9067ED935C1Q35250665-72F51BB7-19B9-4CC1-88D7-C8389C1EE46FQ35338096-E26C36D9-D682-4983-AD47-AE0F69A6C3C4Q35369261-62266D00-E96E-4023-B065-F7C3F3983304Q35492338-C94C8938-344A-4432-9896-134CD9D9E0EBQ35562568-80FEEE97-2102-4AC6-855B-E88EFC34516AQ35614719-87A8426B-C45F-4FBC-B100-7E97918E32FDQ35670873-04E7D2C8-94DB-4DEF-8894-146AA215E9AAQ35833512-E58C4758-B51D-4BA6-93D5-DFEAA1172CEAQ36025409-C55C6E36-8737-4DC4-AB96-78F01D2E8C9CQ36115626-8E436420-4152-4EF2-BDDD-D7B6C9D41082Q36171039-A05CD97D-0CDD-4EB5-A756-F50331665EA5Q36184020-B461D800-3021-4BD5-9D9A-48D432CB6E7F
P2860
Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Treatment with protease inhibi ...... ce in HIV-1-infected patients.
@en
Treatment with protease inhibi ...... ce in HIV-1-infected patients.
@nl
type
label
Treatment with protease inhibi ...... ce in HIV-1-infected patients.
@en
Treatment with protease inhibi ...... ce in HIV-1-infected patients.
@nl
prefLabel
Treatment with protease inhibi ...... ce in HIV-1-infected patients.
@en
Treatment with protease inhibi ...... ce in HIV-1-infected patients.
@nl
P2093
P921
P1433
P1476
Treatment with protease inhibi ...... ce in HIV-1-infected patients.
@en
P2093
Dieterle C
Landgraf R
P304
P356
10.1097/00002030-199815000-00001
P407
P577
1998-10-01T00:00:00Z